| About Us |
|
Innovative Science Solutions (ISS) is a scientific consulting firm founded by Steven Weisman, PhD and David Schwartz, PhD. The company provides business acumen for issues related to pharmaceutical products, foods, medical devices, cosmetics, dietary supplements, and chemical exposures. Since its inception in 2000, ISS has offered comprehensive support solutions ranging from the preparation of simple scientific manuscripts for publication, to the development of complex strategies for product defense programs. The ISS team is made up of scientific experts and highly trained consultants who have extensive experience serving industry and counsel. Our professionals have access to the world's preeminent thought leaders and utilize strategic alliances with multiple organizations to provide a wide breadth of services. We work hand-in-glove with our associates so that our clients can keep pace with the evolving business environment of medical and chemical science.
Steven M. Weisman, PhD | Head, Global Healthcare ProductsSteven M. Weisman, PhD | Head, Global Healthcare Products
Dr. Weisman has over 20 years of experience in pharmacology, toxicology, pharmaceutical product development, clinical and regulatory affairs, and marketing evaluation and communication. He played a leading role in the pharmaceutical industry’s response to the removal of PPA (phenylpropanolamine) from over-the-counter products. He's worked extensively on management initiatives for opiate safety, antibiotic drug resistance, and emergency contraceptives. He's even credited with establishing the safety and continued marketing of artificial fingernail products. Dr. Weisman is a leading authority on the switch of prescription-only products to over-the-counter status and is widely published in these areas. His development and support work includes shepherding the analgesic, Aleve, from a prescription-only product to its popular over-the-counter form, and promoting the cardiovascular uses of aspirin for heart attack and stroke prevention. He is also recognized for effective regulatory strategies that maximize the global market potential of regulated products. His expertise in claim substantiation has helped clients successfully defend against challenges to their marketing initiatives and saved them millions of dollars. Prior to founding ISS he ran the Pharmaceutical and Food practices at a major scientific consulting firm in Washington, DC. Before that, he served as Global Director of Medical and Clinical Affairs at Bayer, Director of Strategic Research at Sterling Winthrop, and held similar positions at Hoffman La Roche and Procter & Gamble. He has organized and presented at numerous symposia, FDA advisory committee meetings, and other regulatory venues, worldwide. He manages the FDA advisory committee process for many of the largest pharmaceutical concerns and represents companies before regulatory authorities in major markets around the world. Dr. Weisman received his PhD in Pharmacology from Cornell University Medical College and completed his postdoctoral training in Immunopharmacology at the Roche Institute of Molecular Biology. David H. Schwartz, PhD | Head, Liability SupportDavid H. Schwartz, PhD | Head, Liability Support
Dr. Schwartz has extensive experience designing programs that critically review the scientific foundation for product development and major mass tort litigation. For 20 years, he has worked with the legal community evaluating product safety and defending products such as welding rods, cellular telephones, breast implants, wound care products, dietary supplements, general healthcare products, and a host of pharmaceutical agents (including: antidepressants, dermatologics, anti-malarials, anxiolytics, antipsychotics, and diet drugs). In the course of his work, Dr. Schwartz has played a leading role in winning multi-billion dollar legal cases for clients. He counts the Daubert hearings as his biggest successes. With the sheer weight of scientific data he’s able to collect, evaluate, and present as evidence, he’s helped counsel win cases before going to trial, thereby saving time and money. Prior to founding ISS, Dr. Schwartz served as the Director of Scientific Litigation Support for the law firm, McCarter and English, where he was asked to evaluate the safety of Prozac. Since then, he has guided clients using scientific principles to defend products before, during, and after launch. Dr. Schwartz received a Ph.D. in Neuroscience from Princeton University and postdoctoral training in Neuropharmacology and Neurophysiology from the Center for Molecular and Behavioral Neuroscience at Rutgers University. |
